PD-1 and PD-L1 are usually highly expressed on the surface of activated lymphocytes and tumor cells, respectively, and the combination of the two down-regulates TCR signaling and reduces the production of TNF-α, IFN-γ, and IL-2 (10), which inhibits the tumor-killing function of immune cells. The gene discussed is IL2; the disease is neoplasm.